X0306 4 2019-07-26 0 0001737287 Allogene Therapeutics, Inc. ALLO 0001754937 MOORE ALISON 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Technical Officer Common Stock 2019-07-26 4 M 0 13193 2.27 A 78566 D Common Stock 2019-07-26 4 S 0 13193 29.1817 D 65373 D Common Stock 2019-07-29 4 M 0 23815 2.27 A 89188 D Common Stock 2019-07-29 4 S 0 23815 29.3878 D 65373 D Common Stock 2019-07-30 4 M 0 11819 2.27 A 77192 D Common Stock 2019-07-30 4 S 0 11819 29.845 D 65373 D Stock Option (Right to Buy) 2.27 2019-07-26 4 M 0 13193 0.00 D 2028-06-25 Common Stock 13193 802663 D Stock Option (Right to Buy) 2.27 2019-07-29 4 M 0 23815 0.00 D 2028-06-25 Common Stock 23815 778848 D Stock Option (Right to Buy) 2.27 2019-07-30 4 M 0 11819 0.00 D 2028-06-25 Common Stock 11819 767029 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2019. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $30.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter. /s/ Veer Bhavnagri, Attorney-in-Fact 2019-07-30